Veliparib plus carboplatin and paclitaxel versus investigator's choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer

Authors

Ramaswamy Govindan, Washington University School of Medicine in St. Louis
et al

Journal

Clinical lung cancer

Publication Date

5-1-2022

Volume

23

Issue

3

First Page

214

Last Page

225

Document Type

Open Access Publication

DOI

10.1016/j.cllc.2022.01.005

Rights and Permissions

Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):214-225. doi: 10.1016/j.cllc.2022.01.005. © 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Recommended Citation

Govindan, Ramaswamy and et al, "Veliparib plus carboplatin and paclitaxel versus investigator's choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer." Clinical lung cancer. 23, 3. 214 - 225. (2022).
https://digitalcommons.wustl.edu/oa_4/255